Compare Peloton Interactive Inc (PTON) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Peloton Interactive Inc trades at $5.12 (market cap $2.16B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 59.1× Peloton Interactive Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PTON | VRTX | |
|---|---|---|
Market Cap | $2.16B | $127.55B |
Volume | 11,369,487 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $557.96 |
52-Week Low | $3.71 | $407.37 |
Typical Hold Time | 37 Days | 120 Days |
Enterprise Value | $2.66B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $5.12, up 5.57% today, as the company shows signs of a turnaround with its first profitable year in 2026. Technical indicators remain bearish overall, while fundamentals reveal improving profitability with net income margin turning positive at 2.58%. Recent product launches including the foldable Tread Flex and AI-powered coaching features aim to broaden market appeal. The stock trades well below analyst consensus price target of $8.00, with 50% of analysts maintaining buy ratings despite recent insider selling activity.
PTON presents a turnaround story with improving financial metrics but faces execution risks amid declining subscriber counts. The company's debt-heavy balance sheet and negative shareholder equity remain concerns, though cash flow improvements and cost-cutting measures show progress. Upside potential exists if new product adoption drives subscriber growth, but competition and macroeconomic pressures create headwinds for sustained recovery.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
